Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Frix (Liège, Belgium), F. Schleich (Liège, Belgium), V. Paulus (Liège, Belgium), M. Henket (Liège, Belgium), F. Guissard (Liège, Belgium), R. Louis (Liège, Belgium). Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?. 2524

Member's Comments

No comment yet.

Related content which might interest you: Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Patients with asthma and comorbid allergic rhinitis: Is optimal quality of life achievable in real life? Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018 Year: 2018 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 The comparative assessment of quality of life in asthma patients treated with inhaled steroids Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 What patients with IPF can expect concerning symptoms and quality of life during first six months of antifibrotic treatment? Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019